API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.businesswire.com/news/home/20211220005646/en/Vifor-Pharma-reports-positive-outcome-of-the-phase-IIIb-DIAMOND-trial-of-Veltassa%C2%AE
http://www.pharmafile.com/news/535799/nice-reverses-previous-decision-recommend-vifor-pharmas-veltassa-nhs-treatment-hyperkala
https://www.businesswire.com/news/home/20190510005469/en/Vifor-Pharma%E2%80%99s-Phase-II-AMBER-Study-Meets-Primary/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.businesswire.com/news/home/20190510005469/en/Vifor-Pharma%E2%80%99s-Phase-II-AMBER-Study-Meets-Primary
http://www.pharmatimes.com/news/nice_turns_down_hyperkalaemia_therapies_1257420